This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Study of 3 Doses of ARD-0403 in Testosterone Deficient Men (ARD-0403-001)

This study has been completed.
Information provided by:
Ardana Bioscience Ltd Identifier:
First received: January 8, 2008
Last updated: January 16, 2008
Last verified: January 2008
The purpose of this study is to determine which dose, if any, results in testosterone levels within the normal range for men.

Condition Intervention Phase
Hypogonadism Drug: ARD-0403 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Phase II, Randomized, Double-Blind, Placebo-Controlled, Cross-Over, Multi-Centre Study of the Pharmacokinetics and Tolerability of 3 Different Doses of ARD-0403 in Testosterone Deficient Men

Resource links provided by NLM:

Further study details as provided by Ardana Bioscience Ltd:

Primary Outcome Measures:
  • Pharmacokinetic

Enrollment: 42
Study Start Date: October 2005
Study Completion Date: February 2006
Primary Completion Date: February 2006 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Testosterone deficiency
  • Normal BMI

Exclusion Criteria:

  • Previous treatment with testosterone replacement therapy within 4 weeks
  • Moderate-severe benign prostatic hypertrophy, or prostatic cancer
  • Haematocrit >50%
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00597051

Republican Endocrinology Center Hospital
Minsk, Belarus, 220 007
Sponsors and Collaborators
Ardana Bioscience Ltd
Principal Investigator: Tatiana Mokhort, MD Republican Endocrinology Center Hospital, Minsk, Republic of Belarus
  More Information Identifier: NCT00597051     History of Changes
Other Study ID Numbers: ARD-0403-001
Study First Received: January 8, 2008
Last Updated: January 16, 2008

Additional relevant MeSH terms:
Gonadal Disorders
Endocrine System Diseases
Testosterone enanthate
Testosterone undecanoate
Testosterone 17 beta-cypionate
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Anabolic Agents processed this record on August 18, 2017